Quest Diagnostics to Speak at the William Blair 45th Annual Growth Stock Conference
SECAUCUS, N.J., May 16, 2025 /PRNewswire/ — Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a presentation at the William Blair 45th Annual Growth Stock Conference in Chicago on Tuesday, June 3, 2025, at 11:00 a.m. Eastern Time.
The presentation session will be webcast live during the conference on the company's investor relations page, which can be accessed at ir.QuestDiagnostics.com. In addition, the archived webcast will be available within 24 hours after the conclusion of the live event and will remain available until July 3, 2025.
About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our more than 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
40 minutes ago
- Malaysian Reserve
ThrivePOP Achieves HubSpot Platinum Tier as a HubSpot Solutions Partner, Solidifying Leadership in Digital Marketing Innovation
MUSKEGON, Mich., June 11, 2025 /PRNewswire/ — ThrivePOP, a digital marketing agency recognized for its innovative approach to brand strategy, is pleased to announce its new tier level within the Platinum Tier HubSpot Solutions Partner Program. This significant milestone marks a pivotal moment in the company's growth, reflecting its commitment to delivering exceptional inbound marketing, sales enablement, customer service solutions, and HubSpot Support for its clients. HubSpot's Platinum Tier is reserved for agencies that demonstrate exceptional expertise, outstanding client success, and a profound understanding of the HubSpot ecosystem. ThrivePOP's advancement to this prestigious level shows its ability to deliver results-driven campaigns that foster meaningful customer relationships and drive measurable growth for clients. 'Achieving Platinum status is a testament to our team's dedication to helping businesses thrive through innovative digital marketing strategies,' said Michele Ringleberg, CEO of ThrivePOP. 'As a female-owned agency, we're proud to lead the way in transforming how businesses connect with their audiences. We couldn't have done it without HubSpot's platform to help us deliver real, impactful results.' ThrivePOP's growth to Platinum Partner status reflects its ongoing investment in creative digital tools, strategic content development, and data-driven insights. This new status enables the agency to offer clients even more advanced support, exclusive resources, and enhanced platform capabilities. 'We're excited to continue pushing the boundaries of what's possible in digital marketing,' added Ringleberg. 'This milestone not only reflects our success as an agency but also our commitment to the success of every client we serve.' For more information about ThrivePOP's HubSpot services and how the agency can help your business thrive, visit or contact the team at info@ About ThrivePOPThrivePOP is a full-service digital marketing agency based in Muskegon, Michigan. It specializes in inbound marketing, web design, SEO, content creation, social media, and HubSpot integration and support. With a mission to help businesses thrive in the digital age, ThrivePOP empowers brands to connect with their audiences, drive engagement, and achieve sustainable growth. Contact Name: Michele Ringelberg, CEOCompany: ThrivePOP Digital Marketing AgencyHowdy@ 844.822.5016
Malaysian Reserve
40 minutes ago
- Malaysian Reserve
Multiple Sclerosis Market to Grow Rapidly at a CAGR of 3.8% During the Forecast Period (2025-2034)
The multiple sclerosis market is growing due to rising prevalence, earlier diagnosis, and wider access to care. Demand is fueled by advancements in DMTs and emerging BTK inhibitors, which offer targeted, high-efficacy options, especially for progressive forms with limited existing therapies. LAS VEGAS, June 11, 2025 /PRNewswire/ — Multiple sclerosis is a long-term autoimmune disorder in which the immune system mistakenly attacks the protective sheath surrounding nerves in the brain and spinal cord. This interference disrupts the flow of signals between the brain and the rest of the body, leading to symptoms such as fatigue, muscle weakness, vision disturbances, and difficulty with mobility. The severity and progression of multiple sclerosis can vary greatly among individuals. As of 2024, there were an estimated 1.6 million diagnosed cases of multiple sclerosis across the 7MM. This number is expected to increase at a CAGR of 1.4% over the forecast period from 2025 to 2034. The therapeutic landscape for multiple sclerosis has undergone a significant transformation, spurred by progress in both drug-based and supportive treatment approaches. Although MS remains without a cure, the market is seeing an expanding array of disease-modifying therapies (DMTs), greater personalization of care, and innovations in how treatments are delivered—all aimed at enhancing patient outcomes and quality of life. Pharmacologically, multiple sclerosis treatment involves both immediate and long-term strategies. For managing acute relapses, high-dose intravenous corticosteroids, most commonly methylprednisolone, continue to be the primary treatment, usually given over 3 to 5 days and followed by a course of tapering oral steroids. Learn more about the multiple sclerosis therapeutics market @ Multiple Sclerosis Drugs Market Intravenous corticosteroids, such as methylprednisolone, are effective for treating acute multiple sclerosis relapses but do not impact the long-term course of the disease. Ongoing disease management relies on disease-modifying therapies (DMTs), selected based on the severity of MS and individual patient requirements, to reduce relapse frequency and delay disability progression. While older injectable multiple sclerosis treatments like PLEGRIDY are still used, newer oral options like MAYZENT, VUMERITY, and MAVENCLAD provide greater convenience and may improve patient adherence. High-efficacy monoclonal antibodies (mAbs), including OCREVUS (now also available in a subcutaneous form), KESIMPTA, and BRIUMVI, are increasingly preferred for home-based therapy. Although LEMTRADA is a potent option, its use is restricted due to safety risks and its inclusion in the REMS program. As key multiple sclerosis drugs such as TYSABRI, TECFIDERA, AUBAGIO, and GILENYA face generic competition, pricing and access are being reshaped. In response, originator companies are shifting focus to next-generation treatments and improved formulations, such as subcutaneous versions and enhanced safety features, to retain market share. Supportive therapies also play a critical role; rehabilitation via exercise and physiotherapy can improve mobility and reduce fatigue, especially in progressive multiple sclerosis. Cognitive behavioral therapy (CBT) and mindfulness strategies help manage mood disorders like depression and anxiety, which in turn support treatment adherence. Additionally, lifestyle modifications involving diet, sleep hygiene, and vitamin D intake aid in symptom control. Assistive devices and occupational therapy further promote independence and enhance quality of life. Find out more on FDA-approved multiple sclerosis medication @ Multiple Sclerosis Treatments Multiple sclerosis treatment lacks neuroprotective and remyelinating therapies, with limited options for progressive multiple sclerosis. Current drugs focus on immune modulation but fail to reverse damage or halt progression. Diagnostic delays remain common due to nonspecific symptoms and limited biomarkers. There is a critical need for early detection tools, personalized therapies, and agents targeting neurodegeneration to improve outcomes in multiple sclerosis. The multiple sclerosis treatment pipeline remains robust, with promising candidates like Remibrutinib, Tolebrutinib, Fenebrutinib, and CNM-Au8 targeting novel mechanisms such as BTK inhibition and neuroprotection. Other multiple sclerosis drugs in the pipeline include Frexalimab (SAR441344) (Sanofi), Vidofludimus calcium (IMU-838) (Immunic Therapeutics), Masitinib (AB Science), PIPE-307 (Contineum Therapeutics), and others. These multiple sclerosis pipeline therapies reflect an increasing emphasis on progressive multiple sclerosis and remyelination to improve long-term outcomes. Discover which therapies are expected to grab major multiple sclerosis market share @ Multiple Sclerosis Treatment Market Tolebrutinib is an oral BTK inhibitor designed to penetrate the blood–brain barrier, targeting both B cells and microglia to mitigate smoldering neuroinflammation in multiple sclerosis (MS). By focusing on central nervous system (CNS) processes that drive neurodegeneration, it aims to address disease progression beyond peripheral inflammation. In March 2025, the US FDA accepted tolebrutinib for priority review as a treatment for non-relapsing secondary progressive multiple sclerosis, to slow relapse-independent disability progression. A decision is anticipated by September 2025, with a parallel evaluation ongoing in the EU. Vidofludimus calcium is an investigational oral therapy currently in Phase III trials for relapsing multiple sclerosis and Phase II for progressive multiple sclerosis. It combines DHODH inhibition for immune regulation with Nurr1 activation for potential neuroprotective effects, aiming to target key mechanisms of neurodegeneration. In April 2025, Immunic reported positive outcomes from the Phase II CALLIPER trial, supporting vidofludimus calcium's role as a Nurr1 activator in progressive multiple sclerosis patients. Fenebrutinib is an innovative, oral, reversible, non-covalent BTK inhibitor in Phase III development for MS. By modulating both adaptive and innate immune responses via B cells and microglia, it offers a dual approach to controlling disease activity and slowing disability. It is currently the only reversible BTK inhibitor in late-stage multiple sclerosis trials. The Phase III program includes FENhance 1 and 2 studies in relapsing multiple sclerosis (vs. teriflunomide) and the FENtrepid trial in primary progressive multiple sclerosis (vs. ocrelizumab), marking the first head-to-head comparison of a BTK inhibitor with an approved PPMS therapy. Regulatory submissions for both RMS and PPMS are planned for 2026. In September 2024, Roche presented 48-week results from the FENopta Phase II open-label extension at the 40th ECTRIMS Congress. Remibrutinib is an oral covalent BTK inhibitor under investigation for multiple sclerosis and chronic spontaneous urticaria (CSU), where it blocks BTK signaling to prevent histamine release. While no Phase I or II trials have yet been conducted for multiple sclerosis, remibrutinib is in Phase III development for CSU through the REMODEL-1 and REMODEL-2 trials. Primary completion is expected in 2026, with regulatory submission anticipated in 2027. Earlier Phase IIb CSU data showed favorable safety and tolerability. CNM-Au8 is an oral gold nanocrystal therapy designed to address mitochondrial dysfunction in multiple sclerosis by boosting NAD+ production, enhancing antioxidant capacity, and activating the heat shock factor-1 pathway to support protein homeostasis. Although the VISIONARY-MS Phase II trial was halted early due to COVID-19, CNM-Au8 is being evaluated in the ongoing Phase II REPAIR-MS trial. Results from REPAIR-MS, along with a planned FDA End-of-Phase II meeting in 2025, will inform the design of a global Phase III trial. In April 2025, Clene Nanomedicine presented promising new data at the AAN Annual Meeting, showing meaningful improvements in cognition and visual function from the VISIONARY-MS open-label extension. Masitinib is being developed for progressive multiple sclerosis with a focus on inhibiting mast cells and microglia, key players in chronic neuroinflammation. This approach aims to slow progression in patients with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive multiple sclerosis (SPMS). Following positive results from a Phase IIb/III study, a confirmatory Phase III trial is ongoing. In September 2024, AB Science provided an update on masitinib's development at the ECTRIMS 2024 conference. Discover more about the multiple sclerosis pipeline @ Multiple Sclerosis Clinical Trials The anticipated launch of these emerging therapies for multiple sclerosis are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the multiple sclerosis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for Multiple Sclerosis is expected to grow from USD 20 billion in the 7MM in 2024 at a 3.8% CAGR by 2034. This expansion across the 7MM will be driven by the introduction of innovative therapies, remibrutinib, tolebrutinib, fenebrutinib, frexalimab, vidofludimus calcium, CNM-Au8, and masitinib, among others. Furthermore, multiple sclerosis prevalence is rising due to modifiable environmental and lifestyle factors like Epstein-Barr virus, low vitamin D, smoking, obesity, and night shifts, with genetics and geography also contributing. DelveInsight's latest published market report, titled Multiple Sclerosis – Market Insight, Epidemiology, and Market Forecast – 2034, will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the multiple sclerosis country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The multiple sclerosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Diagnosed Prevalent Cases of Multiple Sclerosis Gender-specific Diagnosed Prevalent Cases of Multiple Sclerosis Phenotype-specific Diagnosed Prevalent Cases of Multiple Sclerosis EDSS-specific Diagnosed Prevalent Cases of Multiple Sclerosis The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM multiple sclerosis market. Highlights include: 10-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this multiple sclerosis market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the multiple sclerosis market. Also, stay abreast of the mitigating factors to improve your market position in the multiple sclerosis therapeutic space. Related Reports Multiple Sclerosis Epidemiology Forecast Multiple Sclerosis Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted multiple sclerosis epidemiology in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan. Multiple Sclerosis Pipeline Multiple Sclerosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key multiple sclerosis companies, including Sanofi, Immunic, InnoCare Pharma, Tiziana Life Sciences, Biogen, Bristol-Myers Squibb, ImStem Biotechnology, Idorsia Pharmaceuticals, among others. Relapsing-Remitting Multiple Sclerosis Market Relapsing-Remitting Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key RRMS companies including Mapi Pharma, Apimeds, Genentech (Roche), Merck, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, among others Relapsing-Remitting Multiple Sclerosis Pipeline Relapsing-Remitting Multiple Sclerosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key RRMS companies, including TG Therapeutics, Novartis, Sanofi, CinnaGen, Immunic, Mapi Pharma, Apimeds, Genentech (Roche), Merck, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, GeNeuro SA, GlaxoSmithKline, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content:
Malaysian Reserve
2 hours ago
- Malaysian Reserve
Natural Grocers® Celebrates National New Mexico Day with a Special Gift and Savings, June 14-16, 2025
Family-Operated grocer offers New Mexico {N}power® members a free state-themed Natural Grocers reusable bag and additional in-store savings LAKEWOOD, Colo., June 11, 2025 /PRNewswire/ — Natural Grocers®, the leading family-operated organic and natural grocery retailer in the U.S., invites customers to its second annual 'Celebrate New Mexico' event, June 14-16, at its six New Mexico locations. In honor of National New Mexico Day, {N}power® members will receive a free, limited-edition, state-themed Natural Grocers reusable bag, and a $5-off coupon toward in-store purchases. NEW MEXICO PROUDHeadquartered in Colorado, Natural Grocers expanded its roots south to the 'Land of Enchantment' in August of 2003. Today the company operates six stores across New Mexico, with a seventh location coming to Ruidoso, later this year. Albuquerque – Wyoming Blvd NE Farmington Las Cruces Los Alamos Rio Rancho Santa Fe Ruidoso (COMING SOON)* *Join Natural Grocers' Recruiting Team at the Ruidoso Hotel on June 24 from 4-6PM for a Community Meet and Greet to learn more about the new location and available career options. NEW MEXICO {N}POWER® MEMBERS SAVE & CELEBRATENatural Grocers will be celebrating National New Mexico Day by honoring its customers with a freebie and extra savings for {N}power members from June 14-16, 2025. June 14-16: All {N}power members at all New Mexico stores will receive a FREE, limited-edition, reusable shopping bag featuring each of the 21 states Natural Grocers has a presence in—including New Mexico, while supplies last.[i] June 14-16: {N}power members will enjoy extra savings with a $5 off coupon.[ii] SIGN UP & SAVENot an {N}power member? Not a problem! Discover {N}power, Natural Grocers' free customer rewards program, and enjoy exclusive discounts, deals, and surprise offers. You'll earn valuable rewards points with every visit. Customers can sign up for {N}power here.[iii] Customers can also download the Natural Grocers App for easy access to {N}power benefits and more. A COMMITMENT TO NEW MEXICO CREW:Natural Grocers provides careers for over 160 Crew members in the state of New Mexico. The company is passionate about ensuring that its employees can live a healthy, balanced life. Natural Grocers is committed to positively impacting Crew's physical, emotional and financial well-being with free nutrition education programs, excellent benefits and access to the highest quality, affordably priced products. Click here to learn more about career options with Natural Grocers (search by store and state – including New Mexico). LEARN MORE Subscribe to the Free Health Hotline® Magazine to learn more about a natural approach to living with monthly sale items, recipes and educational articles. To keep up with the latest that Natural Grocers has to offer, follow them on Facebook, Instagram, TikTok or YouTube. For media inquiries or sample requests, please email kmacarelli@ ABOUT NATURAL GROCERS BY VITAMIN COTTAGEFounded in 1955, Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) is an expanding specialty retailer of natural and organic groceries, body care products, and dietary supplements. The grocery products sold by Natural Grocers must meet strict quality guidelines and may not contain artificial flavors, preservatives, or sweeteners (as defined by its standards), synthetic colors, or partially hydrogenated or hydrogenated oils. The Company sells only USDA-certified organic produce and exclusively pasture-raised, non-confinement dairy products, and free-range eggs. Natural Grocers' flexible smaller-store format allows it to offer affordable prices in a shopper-friendly, clean, and convenient retail environment. The Company also provides extensive free science-based Nutrition Education programs to help customers and Crew make informed health and nutrition choices. Natural Grocers is committed to its 5 Founding Principles—including its 'Commitment to Community' and 'Commitment to Crew'. In fiscal year 2024, the Company invested more than $15 million in incremental compensation and discretionary payments for Crew. Headquartered in the Union Square neighborhood of Lakewood, CO, Natural Grocers has 169 stores in 21 states. Visit for more information and store locations. [i] Offer available only to {N}power members. Limit one bag per customer. Only valid 6/14/25 to 6/16/25 at participating New Mexico stores, while supplies last. Quantity limited to stock on hand; no rain checks. [ii] Offer available only to registered {N}power members, for in store purchases at participating New Mexico Natural Grocers stores, 6/14/25 to 6/16/25. Customer must load the reward via {N}power email or app prompt before shopping. $5 discount will be applied to product's regular non-discounted price. A minimum purchase of $25 is required to use the $5 off coupon. Must present phone number at checkout to accumulate towards the $25 requirement in one transaction. [iii] Sign up by 6/14/25 to receive this coupon via email or app. {N}power® offers are available only to registered members and are subject to program terms and conditions available at and privacy available at Natural Grocers reserves the right to correct errors. Void where prohibited by law. Natural Grocers employees, including members of their household, are not eligible.
